ArticleAmerican journal of translational research2026
Effect of famciclovir combined with nerve block on acute pain in patients with herpes zoster.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo evaluate the efficacy of famciclovir in combination with nerve block treatment for managing acute pain in patients with herpes zoster.
methodsThis retrospective study included 200 patients with acute pain due to herpes zoster, admitted to our hospital between January 2021 and January 2025. Participants were divided into two groups: the observation group (n = 108; famciclovir combined with nerve block therapy) and the control group (n = 92; nerve block therapy alone), according to their treatment protocols. Pain intensity was assessed using the Visual Analog Scale (VAS) at baseline, Day 3, Day 7, and Day 14. Secondary outcomes included inflammatory markers, sleep quality (Pittsburgh Sleep Quality Index [PSQI], Sleep Disturbance Scale [SDS], Epworth Sleepiness Scale [ESS], and Insomnia Severity Index [ISI]), adverse events, and clinical outcomes, such as rash resolution and postherpetic neuralgia (PHN) incidence.
resultsThe observation group experienced greater reductions in VAS scores on Days 3, 7, and 14 compared with the control group (P < 0.001), indicating better pain relief. Inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin (PCT), tumor necrosis factor-α (TNF-α), and white blood cell count (WBC), were significantly lower in the observation group (P < 0.001 for all), indicating a stronger anti-inflammatory response. Sleep quality also improved significantly in the observation group, evidenced by reductions in PSQI, SDS, ESS, and ISI scores (P < 0.001 for all). The incidence of adverse events was similar between the two groups (P > 0.05), with no severe events. In addition, the observation group also showed better clinical manifestations, including higher rates of pain relief (P = 0.001) and rash resolution (P < 0.001), as well as a lower incidence of PHN (P < 0.001).
conclusionThe combination of famciclovir and nerve block therapy substantially improves pain relief, reduces inflammatory responses, and enhances clinical outcome without increasing the risk of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.